Pfizer BNT 162b2 COVID-19 vaccine-induced fulminant myopericarditis: A case study.
- Resource Type
- Report
- Authors
- Montarello NL; Department of Cardiology, The Royal Adelaide Hospital, Adelaide, South Australia, Australia.; The University of Adelaide, Adelaide, South Australia, Australia.; Wong HZ; Department of Intensive Care, The Royal Adelaide Hospital, Adelaide, South Australia, Australia.; Jeffries A; Department of Cardiology, The Royal Adelaide Hospital, Adelaide, South Australia, Australia.; Perkins GB; The University of Adelaide, Adelaide, South Australia, Australia.; Immunology Directorate, SA Pathology, Adelaide, South Australia, Australia.; Hissaria P; The University of Adelaide, Adelaide, South Australia, Australia.; Department of Immunology, The Royal Adelaide Hospital, Adelaide, South Australia, Australia.; Immunology Directorate, SA Pathology, Adelaide, South Australia, Australia.; Stokes MB; Department of Cardiology, The Royal Adelaide Hospital, Adelaide, South Australia, Australia.; Raith E; The University of Adelaide, Adelaide, South Australia, Australia.; Department of Intensive Care, The Royal Adelaide Hospital, Adelaide, South Australia, Australia.; Teo K; Department of Cardiology, The Royal Adelaide Hospital, Adelaide, South Australia, Australia.; Bradley J; Department of Cardiology, The Royal Adelaide Hospital, Adelaide, South Australia, Australia.; The University of Adelaide, Adelaide, South Australia, Australia.
- Source
- Publisher: Elsevier B.V. on behalf of College of Intensive Care Medicine of Australia and New Zealand Country of Publication: Netherlands NLM ID: 100888170 Publication Model: eCollection Cited Medium: Print ISSN: 1441-2772 (Print) Linking ISSN: 14412772 NLM ISO Abbreviation: Crit Care Resusc Subsets: PubMed not MEDLINE
- Subject
- Language
- English
- ISSN
- 1441-2772
The use of mRNA COVID-19 vaccine can on rare occasions cause life-threatening, fulminant myopericarditis. This case report demonstrates previously reported benefit of early use of venoarterial extracorporeal membrane oxygenation mechanical assistance and supports the use of intravenous highly purified immunoglobulin pharmacotherapy to help achieve a good clinical outcome.
(© 2023 The Authors.)